ALN-2232 Phase is an Alnylam Pharmaceuticals, Inc. program in obesity and weight management. Its next catalyst is a Readout in Feb 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Obesity and weight management. Sponsor: Alnylam Pharmaceuticals, Inc. (ALNY). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for ALN-2232 Phase is a Readout in Feb 2027.
No FDA decision for ALN-2232 Phase is in our archive yet.
In our records ALN-2232 Phase is under review or in development for Obesity and weight management.
Alnylam Pharmaceuticals, Inc. (ALNY).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.